logo
  

Why Ocugen Is Rising In Pre-market?

Ocugen, Inc. (OCGN) said its partner, Bharat Biotech, posted positive results from a phase 2 analysis of the vaccine candidate, COVAXIN, in participants ages 12-64, receiving a booster dose six months following a second dose on the pre-print server, medRxiv. The analysis showed that participants receiving a booster dose saw a significant increase in neutralizing titers. Additional data found that more than 75 percent of all participants had a detectible neutralizing antibody response six months post their second dose of COVAXIN. The booster dose analysis also found no serious adverse events, the company noted.

COVAXIN is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

Shares of Ocugen were up 6% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
America New York Ri Wang Food Group Co., Ltd. is recalling around 14,635 pounds of ready-to-eat or RTE pork sausage products due to possible contamination with extraneous materials, specifically metal, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The TJX Companies, Inc. (TJX) said its first-quarter pretax profit margin and earnings per share, each on an adjusted basis, exceeded its plans even though sales were slightly below planned range. Adjusted pretax margin was 9.4%, excluding a 1.9 percentage point charge related to a write-down of the... Apple Inc. is delaying its latest plan to ask employees to come back to the office three days a week, but will continue with its plan of two days in office a week, Bloomberg reported. Citing an internal memo, the report also said the tech major is again requiring its staff to wear masks in common spaces, meeting rooms, hallways, and elevators, as well as at 100 US stores.
RELATED NEWS
Follow RTT